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Obesity constitutes one of the most important metabolic diseases being associated to
insulin resistance development and increased cardiovascular risk. Association between
obesity and cancer has also been well established for several tumor types, such as breast
cancer in post-menopausal women, colorectal, and prostate cancer. Cancer is the first
death cause in developed countries and the second one in developing countries, with high
incidence rates around the world. Furthermore, it has been estimated that 15–20% of all
cancer deaths may be attributable to obesity. Tumor growth is regulated by interactions
between tumor cells and their tissue microenvironment. In this sense, obesity may lead to
cancer development through dysfunctional adipose tissue and altered signaling pathways.
In this review, three main pathways relating obesity and cancer development are exam-
ined: (i) inflammatory changes leading to macrophage polarization and altered adipokine
profile; (ii) insulin resistance development; and (iii) adipose tissue hypoxia. Since obesity
and cancer present a high prevalence, the association between these conditions is of great
public health significance and studies showing mechanisms by which obesity lead to can-
cer development and progression are needed to improve prevention and management of
these diseases.
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INTRODUCTION
Obesity has reached epidemic proportions constituting one of the
most important diseases of this century (1). Despite body mass
index (BMI) being used for a long time as the best way to diagnose
and define obesity, recent studies have proposed that BMI mis-
classified subjects with increased cardiovascular risk factors (2).
This finding highlights that BMI underestimates the real preva-
lence of overweight and obesity, since it only considers weight and
height of the patients and not total body fat, which really defines
the obesity-associated comorbidity risk. In this regard, other indi-
cators to determine the prevalence of obesity have been proposed
with body fat percentage being one of the most useful due to its
superior ability to stratify patients according to their metabolic
and cardiovascular risks (3, 4).
Health care expenditure in severe obesity (BMI≥ 40 or
≥35 kg/m2 with manifest serious comorbidities) is greater than
the investment in any other medical condition (5). This is not
only due to direct consequences of obesity, but also due to their
associated comorbidities. There are numerous evidences of the
relationship between obesity and type 2 diabetes mellitus (T2D)
(6), non-alcoholic fatty liver disease (NAFLD) (7, 8) and other
chronic liver diseases such as cirrhosis (9), obstructive sleep
apnea (OSA) syndrome (10), other respiratory alterations (11)
as well as cardiovascular diseases (CVD) including cerebrovascu-
lar disorders and hypertension (12–14). Furthermore, evidence
about the relationship between obesity and several types of can-
cer is increasing (15–19). These tumors include colon, breast,
endometrium, prostate, thyroid, renal, esophagus, gastric cardia,
pancreas,gallbladder,and liver cancer as well as non-Hodgkin lym-
phoma and multiple myeloma (15, 20–23). Nowadays, cancer is
probably one of the most important diseases due to its high preva-
lence and mortality rates (24). According to the National Cancer
Institute, a total of 1,660,290 new cancer cases and 580,350 cancer
deaths would take place in the United States in 2013 (25). Increas-
ing trends in incidence of the most common cancers in Europe are
also of concern, in particular for colorectal cancer, where incidence
is high and still continues to increase (26, 27). A large proportion
of the studied cancers are potentially avoidable (28), and several
programs to prevent or detect early stages of cancer have been pro-
posed, such as gynecologic or colon cancer population screenings
(29–31). Importantly, it has been estimated that 15–20% of all
cancer deaths in the United States can be attributed to overweight
and obesity (32–34). Obesity and cancer affect millions of people
with important consequences; thereby a comprehensive approxi-
mation to the mechanisms underlying their relationship is needed
to ensure better prevention and treatment strategies.
Higher BMIs have been associated with increased risk of dis-
ease while at the same time they have been related with a lower
mortality and a better outcome in several chronic diseases (35).
This paradoxical finding is shared over a variety of cardiovascular,
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pulmonary, and renal diseases and is known as the obesity para-
dox (36). There is increasing evidence that patients, especially
elderly, with elevated BMI and several chronic diseases exhibit
lower all-cause mortality compared with normal-weight patients
(37). However, it should be highlighted that the BMI is an anthro-
pometric marker that does not consider total body fat mass and
distribution, nutritional status, or other factors influencing health
risks (2, 3, 38).
RELATIONSHIP BETWEEN OBESITY AND CANCER
Large prospective studies show a significant association between
excess adiposity and several cancers. There is sufficient evidence
relating obesity and tumor development of the colon, breast
(post-menopausal women), and prostate among others (18).
Breast cancer is the most frequently diagnosed cancer globally
and the second cause of cancer death in women. It has been esti-
mated that breast cancer constituted 30% of all new cancer cases
in women in 2013 (25). Overweight and obesity are important risk
factors for breast cancer development and, in contrast to other risk
factors, such as menstruation age, familiar antecedents or aging,
both overweight and obesity are preventable. It has been shown
that post-menopausal obese women present a threefold increase in
the risk of breast cancer compared to the non-obese control group
(39). Moreover, other studies have revealed that higher BMI is
associated with worse response to neoadjuvant chemotherapy and
worse overall survival (40). Other anthropometric measurements,
such as the waist-to-hip ratio, also correlate with breast cancer
death risk (41). Worse prognosis or survival rates in obese women
with breast cancer have been established in different studies (42–
44), showing that obesity is an important risk factor for breast
cancer and, therefore, therapeutic measures must be adopted to
reduce obesity incidence. It is important to take into account
that hormone replacement therapy (45, 46) and mammographic
density (47) could be additional confounders in these association
studies. The obesity-associated increased risk of post-menopausal
breast cancer might be explained by higher rates of peripheral con-
version of androgenic precursors to estradiol due to an increased
aromatase enzyme activity in adipose tissue (48).
Globally, colorectal cancer remains the third most commonly
diagnosed in males and the second in females with a cumulative
life risk of developing colorectal cancer of 5% in the general popu-
lation (49). Although both, the incidence and mortality have been
slowly but steadily decreasing, colorectal cancer is the third lead-
ing cause of cancer-related deaths (25). The relationship between
obesity and colon cancer is well established (50–53). In this regard,
it has been estimated that about 30% of all colon cancer cases
could be attributable to a BMI higher than 22.5 kg/m2 (54). BMI
appears to be consistently associated with an increased risk of col-
orectal cancer in men, but only a weak association in women has
been described (48). This gender difference might be explained
by sex differences in prevalence and age of the onset of meta-
bolic syndrome, or by a protective effect of estrogens, inducing
apoptosis and inhibition of cell proliferation (55, 56). However,
a recent meta-analysis showed that BMI is positively related with
colon cancer in both men and women, and no gender differences
were found (57). In this sense, a positive association between
BMI and prevalence of colonic adenoma and advanced polyps
has been demonstrated in pre-menopausal women according to
hormonal status (58). Obesity has also been associated with worse
cancer outcomes, such as recurrence of the primary cancer or
increased mortality. Several factors, including reduced sensitiv-
ity to antiangiogenic–therapeutic regimens, might explain these
differences. The underlying mechanisms linking obesity to col-
orectal cancer are not completely elucidated, but inflammation,
insulin resistance, and a dysregulated adipokine profile are pro-
posed as important factors. Other biological factors such as the
gut microbiota (59) or bile acid concentrations are emerging as
novel influential factors in obesity-associated tumors (55).
Prostate cancer is the second diagnosed cancer and the sixth
cause of cancer-related mortality among men worldwide (60).
Because obesity and prostate cancer affect substantial proportions
of the male population, the association between these conditions is
of great public health significance. In the last decade, multiple epi-
demiologic studies have suggested that obesity is associated with
an increased risk of death from numerous cancer types including
prostate cancer (32, 48). Three meta-analyses reported a posi-
tive association between obesity and prostate cancer incidence
and, although modest, the relative risks were consistent (48, 61,
62). Obesity has also been associated with worse prognostic and
malignant transformation of epithelial cells (63, 64). However,
there are contradictory studies about the link between obesity and
prostate cancer (65) reporting no association (64, 66), and even a
protective effect of obesity (67–71). Proposed obesity-associated
alterations related to prostate tumor development include lower
levels of sex hormone-binding globulin that increase the fraction
of biologically available testosterone (15).
Lung cancer is the main cause of cancer-related death in both
genders, with an estimated incidence of more than 200,000 cases in
2013 in the United States (25). To date, the relationship between
obesity and the incidence of lung cancer remains unclear (72).
Controversy still focuses on the effect of smoking in studies inves-
tigating the relationship between BMI and lung cancer (73). In
case–control studies, odds ratios for lung cancer by levels of BMI
showed an increasing linear trend with a lower threshold BMI for
current smokers and ex-smokers of both sexes (74, 75). Moreover,
an inverse association between BMI and lung cancer has been
shown in other studies after adjusting for smoking or waist cir-
cumference (76–78). In this sense, a recent meta-analysis indicates
that overweight and obesity are protective factors against lung can-
cer, especially in current and former smokers (72). Recently, the
involvement of adipokines in lung cancer is under study due to
their emerging carcinogenic and immunomodulatory properties,
making them potential mediators of the complex and still unclear
multistep carcinogenetic process (79).
Association with obesity has also been proposed for other
cancer types, as thyroid, kidney, esophagus, gastric cardia, pan-
creas, gallbladder, or liver cancer, but further studies are needed to
confirm the obesity-attributable risk of tumor development.
DYSFUNCTIONAL ADIPOSE TISSUE IN OBESITY AND TUMOR
DEVELOPMENT
Obesity is described as an excess of adiposity due to a prolonged
status of positive energy balance, which leads not only to changes
in adipose tissue distribution but also to metabolic alterations as
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well as altered cytokine and lipid secretion profiles. Energy balance
and fuel homeostasis require a tight equilibrium between energy
intake (chemical energy from diet-derived macronutrients) and
energy expenditure [basal metabolic rate plus mechanical energy
by muscle contractions due to physical activity (PA)] that are reg-
ulated by both central and peripheral mechanisms. In this sense,
substantial changes have occurred in the patterns of foods con-
sumed with special concern about excess of sugar intake in the
diet in many industrialized countries mainly as sugar-sweetened
drinks (80, 81).
There are two main types of adipose tissue, white and brown,
with different origins and functions (82). The major role of white
adipose tissue (WAT) is related to maintaining energy homeosta-
sis by storing triglycerides and releasing fatty acids for energy
synthesis. It has been well established that WAT also controls a
wide variety of functions including immune and inflammatory
regulation, glucose and lipid homeostasis, food intake control, or
metabolism by secreting a great number of adipokines (83, 84).
WAT is a heterogeneous tissue, consisting of a peripheral subcu-
taneous component (SAT) and a central intra-abdominal com-
ponent [visceral adipose tissue (VAT)] (85). Abdominal obesity
seems to be of greater pathophysiological concern than subcuta-
neous fat with an increase in VAT being strongly correlated with
the metabolic syndrome and tumor development (86–88). Brown
adipose tissue (BAT) was initially described to play a physiological
role in animals and infants. In human neonates, BAT is located
in specific depots, the interscapular and axillary region, and to a
lesser extent, near to the thymus and in the dorsal midline region
of the thorax and abdomen (89). However, recent studies using
positron emission tomography imaging techniques documented
the presence of functional BAT in adult humans (90–92). BAT is
specialized in thermogenesis, the production of heat mainly medi-
ated by the uncoupling protein-1 (UCP-1), which produces heat by
uncoupling mitochondrial respiration for ATP synthesis (93, 94).
Cancer has been associated with cachexia, a complex syndrome
that involves profound metabolic imbalances (95). The colorec-
tal tumor-induced cachexia on BAT in mice has been described,
finding smaller brown adipocytes with profound delipidation in
cachectic tumor-bearing mice (96). Recently, the existence of a
third kind of adipose tissue has been proposed, the “beige” or
“brite” (brown-like adipocytes) adipose tissue (97). Beige adi-
pose tissue is also a thermogenic adipose tissue influenced by
cold-induced signals via the sympathetic nervous system.
Adipose tissue from obese subjects experiments a wide range
of modifications due to its expansion and the excessive amount of
lipids stored. The limitation in adipose tissue expandability leads
to fat accumulation in other parts of the body with lipotoxic con-
sequences (98). Expanded fat depots in obesity are less efficient
in storing dietary fatty acids, so that obese subjects exhibit an
increase in plasma free fatty acids (FFA) and ectopic fat depots. The
higher levels of FFA are susceptible to be substrates for oxidative
processes and also may function as mediators of insulin resistance
in muscle (99) or liver (100, 101). An analysis of cancer-induced
modifications in the lipid profile reveals important clues linking
obesity and cancer. Changes in lipid metabolism may promote
cancer development by an FFA increase, due to its function as
oncogenic signals (18). Reportedly, increased fatty acid synthase
(FASN) activity has been shown in breast cancer cell lines (102),
ovarian tumors (103), or cancer precursor lesions in different
locations (colon, stomach, esophagus, and oral cavity) (104). The
inhibition of the FASN activity reduces the cancer cells’ prolif-
erative capacity, suggesting that FFA act as an energy source for
cancer cells. In addition, some studies show a relationship between
mutations in the FASN enzyme and cancer incidence (105). Fur-
thermore, FASN has been proposed as an important biomarker of
overnutrition-induced insulin resistance (106). Elevated FFA lev-
els derived either from the cancer cell or exogenous fat sources may
promote a more aggressive tumorigenic phenotype with the impli-
cation of monoacylglycerol lipase (107). Finally, different studies
suggest that cancer cells may use lipids directly from adipocytes as
energy source, promoting tumor growth (108).
PATHOPHYSIOLOGICAL MECHANISMS RELATING VISCERAL
ADIPOSE TISSUE EXCESS AND CANCER
Several mechanisms whereby obesity can favor cancer develop-
ment and progression have been proposed, including the obesity-
associated low-grade inflammation, endocrine alterations, insulin
resistance, and hypoxia–angiogenesis processes.
ADIPOSE TISSUE INFLAMMATION, A MICROENVIRONMENT FAVORING
TUMORIGENESIS
Obesity is characterized by a chronic state of low-grade inflam-
mation (109). Adipose tissue is composed of mature adipocytes
and stromal cells, which include preadipocytes, fibroblasts as well
as vascular and immune cells. The interaction between immune
cells and adipocytes leads to inflammation and subsequent adi-
pose tissue dysfunction. Chronic inflammation is characterized by
a sustained response to diverse stress signals, which leads to adi-
pose tissue remodeling (110–112). This process includes adipocyte
hypertrophy, immune cell infiltration, angiogenesis, and fibrosis
during the progression of inflammation (113–116) accompanied
with changes in the adipokine production profile (117). The link
between chronic inflammation and cancer development was first
noticed over 100 years ago by Virchow, when he observed an abun-
dance of leukocytes in neoplastic tissue (118). Since then, the role
of chronic inflammation as a precursor of cancer development has
been observed in multiple cancer types (119). In animal models of
human cancers, inflammation has been shown to influence tumor
promotion and progression (120–122). Like adipose tissue, tumor
microenvironment is composed of multiple cell types includ-
ing epithelial cells, fibroblasts, mast cells, and cells of the innate
and adaptive immune system that favors a pro-inflammatory and
pro-tumorigenic environment (123–127).
Macrophages, obesity, and cancer
Growing evidence reveals that adipose tissue from obese sub-
jects is markedly infiltrated by macrophages that participate in
inflammatory pathways with important roles in obesity-associated
comorbidities (128). Adipose tissue macrophages (ATM) enhance
the levels of inflammatory markers dysregulated in cancer, sug-
gesting that macrophages from peritumoral adipose tissue are
locally involved in promoting carcinogenesis (129–131). The pres-
ence of tumor-associated macrophages (TAM) also contributes
to the pro-inflammatory tumor environment. The recruitment
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
of TAM to the tumor microenvironment is largely dependent
on the monocyte chemoattractant protein-1 (MCP-1). In this
regard, levels of MCP-1 in tumor tissue have been highly correlated
with the accumulation of TAM in ovarian, breast, and pancreatic
cancer (123, 132).
Local environment factors are able to determine polarization of
macrophages through two general states: M1 (pro-inflammatory)
and M2 (anti-inflammatory) macrophages (Figure 1). Activation
of M1 macrophages is mediated mainly through the nuclear fac-
tor κ-light-chain-enhancer of activated B cells (NF-κB) and Jun
N-terminal kinase (JNK)/activator protein-1 (AP-1) system. M1
macrophage-derived tumor necrosis factor (TNF)-α and inter-
leukin (IL)-18, 12, and 23 have been identified as important
mediators in several chronic inflammatory diseases including
obesity and cancer (133–136). Excess of M1 macrophage polar-
ization is related to insulin resistance in obese subjects (137)
with M1 macrophages being also differentiated in the tumor
initiation stages. Obesity could lead to tumor initiation by the
denominated extrinsic pathway, in which tumorigenesis is attrib-
utable to a chronic inflammatory condition through the NF-κB
pathway (138). NF-κB activation in tumor cells promotes car-
cinogenesis by increasing their aggressive potential by trigger-
ing autocrine growth factor cascades and by inhibiting prolif-
eration control mechanisms, including apoptotic signals (139).
NF-κB involvement in tumorigenesis has been shown in vari-
ous tumor models (140). M1 macrophages also contribute to
tumor development by TNF-α and IL-6 signaling, enhancing
carcinogenesis by increasing cell proliferation and neoangio-
genic cell properties (141, 142). In addition, TNF-α produc-
tion by macrophages activates the Wnt/β-catenin pathway, which
is also associated with tumor development by a non-resulting
anti-inflammatory response (143, 144). M2 macrophage acti-
vation is mainly mediated by the IL-4-induced activation of
Janus kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) transduction signaling. It has been shown that IL-10
secreted by M2 macrophages improves insulin signaling, with a
protective role in obesity-induced insulin resistance (145). More-
over, several factors are involved in M2 activation, such as per-
oxisome proliferator-activated receptor (PPAR)-γ, Krüppel-like
factor 4, AMP-activated protein kinase (AMPK), or sirtuin-1
(SIRT1) (146).
In adipose tissue from obese subjects, there is a phenotype
switch from M2 to M1 macrophages leading to an increase in
general inflammatory markers (147). Moreover, during tumor
progression, an M2 to M1 transition of ATM has been shown.
However, in later tumor stages, a trophic and immunomodula-
tory M2-like adipose tissue macrophage phenotype is recruited
to the tumor environment. It has been proposed that M2 dif-
ferentiation could act as a compensatory mechanism, trying to
re-establish a homeostatic environment in a pathological condi-
tion (144). Mechanisms involved in this M1–M2 switch are not
well understood, but molecular pathways related to cyclooxyge-
nase (COX)-2, toll-like receptor (TLR), or Notch signaling have
been proposed to play an important role (148–150). Macrophage
switch from M1 to M2 in tumor setting occurs via many different
receptors, signaling pathways, and transcription factors as a result
of the coexistence of pro- and anti-inflammatory signals present
during tumor progression in the tumor environment.
Dysregulated adipokine profile in obesity and cancer
The progression of tumors toward malignancy requires the inter-
action of various cytokines, growth factors, and transcription
factors. Adipose tissue acts as an important endocrine organ via
the synthesis of several adipokines, which regulate insulin sensitiv-
ity, lipolysis, control of energy intake, or inflammatory processes
(151–153). Obesity affects the secretory profile of adipokines lead-
ing to alteration in multiple physiological processes (154–164).
Adipokines are linked to tumor development and progression due
to their plentiful actions on different cell types, mainly by exert-
ing their effects through inflammatory pathways. Adiponectin
and leptin are two of the most important adipocyte-specific
adipokines.
FIGURE 1 | Macrophages are representative of the innate immune
system and represent a large proportion of the stromovascular cell
fraction in adipose tissue. The phenotype of macrophages depends on
the subset of monocytes upon arrival at target tissues being probably
determined by the local microenvironment. Based on their cytokine
profile secretion and cell surface markers, macrophages are classified
into two main types: the “classical” macrophages named M1 in contrast
to the “alternatively activated” M2. M1 macrophages are the first line of
defense against intracellular pathogens and are classically stimulated by
interferon (IFN)-γ or by lipopolysaccharide (LPS). M1 induce the secretion
of inflammatory cytokines [interleukin (IL)-1, IL-6, tumor necrosis factor
(TNF)-α, or monocyte chemoattractant protein (MCP)-1]. Alternative
activation, resulting from induction by the Th2 cytokines interleukin IL-4
and IL-13, is associated with tissue repair and humoral immunity
producing immunosuppressive factors, including IL-10, IL-1Ra, and
arginase. Obesity and initial tumor stages induce a phenotypic switch
from an anti-inflammatory M2-polarized state to a pro-inflammatory M1
state.
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Adiponectin. Adiponectin, also known as Acrp30, ADIPOQ,
apM1, or GBP28, is a 30-kDa protein mainly secreted by adipocytes
(165). Adiponectin presents a carboxy-terminal globular domain
and an amino-terminal collagen domain that forms characteris-
tic multimers (166). Adiponectin exists as full-length adiponectin
or as a globular fragment. Globular adiponectin is generated
by proteolytic cleavage of full-length adiponectin, but it circu-
lates in very small amounts in the bloodstream (167). Globular
adiponectin exists as a trimer, whereas full-length adiponectin can
be found as a low-molecular weight (trimer), middle-molecular
weight (hexamers), and high-molecular weight (12–18mers) with
different biological functions (168, 169). Both globular and full-
length adiponectin promote an increased fatty acid oxidation
and glucose uptake in the liver and skeletal muscle as well as
a decreased hepatic gluconeogenesis. These biological effects are
mediated by two transmembrane adiponectin receptors, AdipoR1
and AdipoR2, which are expressed in many tissues and activate the
downstream targets AMPK, PPAR-α, and p38 MAPK (167).
Several studies suggest that hypoadiponectinemia or reduced
concentrations of adiponectin and PPAR-α in obesity may be one
of the mechanisms linking obesity and cancer development as
well as progression. Importantly, adiponectin levels are decreased
in obesity-associated insulin resistance (170) and cancer (171). A
negative correlation between adiponectin levels and the risk of
developing colorectal (52, 172, 173), endometrium (174), breast
(175), prostate (176), or pancreas cancer (177) has been shown.
In animal models, a protective role for adiponectin by suppressing
colorectal cancer development has been suggested (178). Adipoq-
knockout mice showed a significant higher polyp formation com-
pared with wild-type mice under a high-fat diet. Furthermore,
it was also demonstrated that Adipor1, but not Adipor2-deficient
mice show an increase in colonic epithelial cell proliferation, sug-
gesting that adiponectin suppresses this biological process under
a high-fat diet (178). Reduced adiponectin levels in the obese state
lead to the development of insulin resistance and compensatory
chronic hyperinsulinemia. Increased insulin levels lead to reduced
liver synthesis and secretion of insulin-like growth factor-binding
protein (IGFBP)-1 and -2, resulting in increased levels of bioavail-
able insulin-like growth factor (IGF)-1. Insulin and IGF-1 promote
cellular proliferation and inhibit apoptosis in many tissue types,
leading to carcinogenesis (15, 171). Low adiponectin levels are
potentially associated with carcinogenesis, indirectly through its
effects on TNF-α and tumor cell proliferation and directly by its
effects on the regulation of hematopoiesis and system, selective
binding to several mitogenic growth factors, and inhibition of
NF-κB (171, 179). The adiponectin protective effects in tumors
also include the inhibition of leptin proliferative signaling and
inducing cell apoptosis (180).
Leptin. Leptin, the OB gene product, acts as a key mediator in
body weight regulation (181–184). In adipose tissue, the secre-
tion levels of leptin are strictly controlled and maintain a balance
to ensure adequate regulation of food intake and energy expen-
diture under physiological conditions. Contrary to adiponectin,
leptin levels are increased in obese individuals (185). Reportedly,
treatment with leptin promotes cell growth, inhibits apoptosis,
and modulates migration of cancer cells (186). In this regard, an
overexpression of leptin receptors in various cancers like breast
(187) or colon (188) has been also shown. Tumor cells from pap-
illary thyroid cancer also show increased expression levels of the
leptin receptor being associated with a more aggressive pheno-
type (189). Mature adipocytes secrete both adiponectin and leptin
with preadipocytes showing a primarily secretion of high lep-
tin levels (190). An increase of the preadipocyte pool in obese
subjects is related to an increase in leptin levels, with proan-
giogenic and promitogenic properties (191). At the same time,
high leptin levels attract more inflammatory cells and promote
monocyte to macrophage differentiation, maintaining the obesity-
associated state of chronic inflammation. In summary, leptin has
an important role in the development of a large variety of malig-
nancies, predominantly acting through the JAK/STAT pathway,
which modulates phosphatidylinositol 3-kinase (PI3K)/Akt and
extracellular signal-regulated kinase (ERK) 1/2 signaling path-
ways increasing the expression of anti-apoptotic proteins (XIAP),
inflammatory markers (TNF-α, IL-6), angiogenic factors [vascular
endothelial growth factor (VEGF)],and also the hypoxia-inducible
factor-1α (HIF-1α). These processes promote cancer cell survival,
proliferation, and migration.
Tumor necrosis factor-α. TNF-α is a pro-inflammatory cytokine
secreted by adipocytes with increased secretion levels in obese sub-
jects (192). TNF-α was first identified as a macrophage-derived
factor that induces the necrosis of tumor cells, but when its
antitumoral activity was tested on cancer patients, a paradoxical
tumor-promoting role became apparent (193–195). At present,
the pro-inflammatory role of TNF-α has been linked to all steps
involved in tumorigenesis, including cellular transformation, sur-
vival, proliferation, invasion, angiogenesis, and metastasis (195,
196). Animal models have shown a positive relationship between
TNF-α and tumor development and progression in liver (197)
and colorectal cancer (195) with elevated circulating concentra-
tions in different tumoral types (198, 199). In addition, TNF-α is
not only produced by a wide variety of tumor cells (200) but also
by adipocytes. Levels of TNF-α are increased in obesity, indicating
a role for this cytokine in the obesity-associated inflammation and
particularly in insulin resistance and diabetes.
Interleukin-6. Interleukin-6 is another major pro-inflammatory
cytokine secreted by adipose tissue, which shows increased lev-
els in obese subjects. It has been implicated in inflammation-
associated carcinogenesis (201, 202). IL-6 modulates the expres-
sion of genes involved in proliferation, survival, and angiogenesis
via the JAK/STAT signaling pathway (203). A relationship between
IL-6 and carcinogenesis has been shown for renal cell carcinoma
(204), gastric cancer (205), or colorectal cancer, among others
(200, 206). Moreover, elevated levels of IL-6 in cancer patients
correlate with disease aggressiveness and poor prognosis (207,
208). Other studies have revealed the role of IL-6 as an anti-
inflammatory cytokine acting via the classic signaling through
the activation of the IL-6 receptor on the cellular membrane of
specific cell types such as macrophages, neutrophils, some T-cells,
and hepatocytes (209, 210).
C-reactive protein. C-reactive protein (CRP) is an acute-phase
reactant protein induced as a response to inflammatory conditions
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and different cytokines including IL-6. Elevated levels of CRP
in adipose tissue and serum of obese subjects have been shown
(211) as well as in patients with a variety of malignancies (212).
Prospective studies have shown a higher risk of developing can-
cer in those with elevated serum CRP (213, 214). Elevated CRP
is a significant predictor of lower survival rates in patients with
several cancers, including esophageal, colorectal, hepatocellular,
pancreatic, urinary bladder, renal, ovarian, and cervical cancer,
after surgical resection. CRP can serve as an additional prognostic
predictor for survival and post-treatment monitoring in cancer
patients (215).
Resistin. Resistin, also known as Fizz3, is a 12-kDa cysteine-rich
protein that plays a role in the development of insulin resistance
and obesity in rodents (216). While adipose tissue constitutes
the main source of resistin in mice, this molecule is secreted
mainly by monocytes and macrophages in humans (217). Human
resistin is implicated in the pathogenesis of atherosclerosis by pro-
moting smooth muscle cell proliferation and migration, ICAM-1
and VCAM-1 expression, as well as via regulating patterns of
adhesion and inflammation in atherosclerotic plaques (218, 219).
Several colorectal cancer studies have shown a positive corre-
lation between resistin and tumor size based on T-staging and
tumor grading (172, 220). Resistin has also been postulated as
a target molecule, which associates with clinicopathological fea-
tures and prognosis of pancreatic ductal adenocarcinoma (221).
Resistin has been postulated as a pro-inflammatory adipokine
(222), exhibiting significantly higher serum levels in patients
affected by breast cancer in comparison to controls. Additionally,
resistin has been proposed as a regulator of the human chorio-
carcinoma cell invasive behavior and endothelial cell angiogenic
processes (223).
Monocyte chemoattractant protein-1. MCP-1 is a chemokine
implicated in the infiltration of macrophages in adipose tissue.
Higher levels of MCP-1 can be found in obese subjects compared
with lean subjects (224). The presence of infiltrating macrophages
as a consequence of increased MCP-1 levels has been shown to
correlate with cancer metastasis and poor prognosis in a variety
of human carcinomas (172, 225). MCP-1 overexpression has been
reported in both ovarian cancer (226, 227) and colorectal cancer
(228).
Visfatin. Visfatin also known as pre-B cell colony enhancing fac-
tor (PBEF) or nicotinamide phosphoribosyltransferase (NAMPT)
is a 52-kDa protein with apparently insulin-mimetic actions (229)
and increased plasma concentrations in patients with obesity and
T2D (230). Since several authors could not replicate the insulin-
mimetic activities of visfatin as well as its ability to bind the
insulin receptor, Fukuhara and colleagues were forced to retract
some of their original findings (231). However, visfatin stimulates
glucose-induced insulin secretion in β-pancreatic cells (232, 233).
Visfatin has been further identified in inflammatory cells with its
levels being reportedly increased in various inflammatory con-
ditions (229). Visfatin has been related with carcinogenesis and
tumor progression, as well as with chemotherapy response (234)
in colorectal (235, 236) and breast cancer (237).
Osteopontin. Osteopontin (OPN), also known as secreted
phosphoprotein-1 (SPP1) and bone sialoprotein-1, among oth-
ers, is a phosphoprotein expressed by a wide variety of cell types,
including adipocytes (238). The expression levels of OPN are
increased in obesity (160, 239) as well as in other pathophysio-
logical processes including neoplastic transformation, progression
of metastases, and promotion of cell survival (240). OPN is also
expressed in many cancers, with elevated circulating levels and tis-
sular tumor expression being associated with poor prognosis in
gastric and liver cancers (241, 242).
Chitinase-3-like protein-1. Chitinase-3-like protein-1 (CHI3L1),
also known as YKL-40 or human cartilage glucoprotein-39, is a
member of mammalian chitinase-like proteins with increased gene
expression levels in obesity and T2D (155, 243). Recently, YKL-40
has been proposed as a new inflammatory marker related to insulin
resistance (244). YKL-40 is also increased in several types of solid
tumors contributing not only to the development of an inflam-
matory state but also to cell proliferation, inhibition of apoptosis,
stimulation of angiogenesis, and regulation of extracellular tissue
remodeling (245). Increased YKL-40 expression has been detected
in glioblastoma multiforme (246), papillary thyroid carcinoma
(247), extracellular myxoid chondrosarcoma (248), colon cancer
(131), and diverse cancer cell lines, being suggested as a useful
cancer prognostic biomarker (249).
Consequences of oxidative stress
Reactive oxygen species (ROS) comprise hydrogen peroxide
(H2O2), superoxide anion (
O2), and hydroxyl radical (HO)
and induce DNA mutations contributing to cancer development
and progression. Potential sources for ROS production in mito-
chondria include xanthine oxidase, cytochrome P450 oxidases,
uncoupled nitric oxide synthases, and NADPH oxidases (250).
Reactive oxygen species exert a wide range of effects in cancer
cells depending on their concentrations. In general, low levels of
ROS are mitogenic and promote cell proliferation and survival,
while intermediate levels cause transient or permanent cell cycle
arrest and induce cell differentiation (251). At high levels, ROS can
easily react with membrane lipids (causing membrane permeabil-
ity alteration), DNA (inducing damage and genomic instability),
and proteins (promoting oxidative modifications that result in less
active enzymes or proteins more susceptible to proteolytic degra-
dation). These facts suggest a possible protective effect of high
local ROS levels in cancer progression (252). However, although
ROS production does not irreversibly alter cell viability, they can
act as a primary messenger, modulating several intracellular sig-
naling cascades leading to cancer progression. Indeed, it has been
demonstrated that ROS activate the MAPK, PI3K/Akt, phospho-
lipase C-γ1 (PLCγ1), protein kinase C, NF-κB, and JAK/STAT
pathways (253). The increase of fat mass in obesity has been cor-
related with the increase of markers of systemic oxidative stress
in both human and mice (254, 255). In this regard, an increase
in the NADPH oxidase subunits in obesity has been described
(254), suggesting that adipose tissue may constitute a source of
ROS, releasing them into the peripheral blood, and affecting the
function of remote organs (256). Adipose tissue from lean subjects
expresses antioxidant enzymes (catalase, superoxide dismutase-1,
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and glutathione peroxidase) for managing ROS production, with
the expression of these antioxidant enzymes downregulated in
adipose tissue from obese individuals (254, 255, 257, 258).
Therapeutic approaches to cancer involving ROS metabolism
have been proposed in recent years. Experimental results have
proposed that the ROS increase is involved in apoptosis induction
by chemotherapeutic anticancer agents (259). Cancer cells with
increased oxidative stress are likely to be more vulnerable to dam-
age by further ROS insults induced by exogenous agents (260).
Therefore, manipulating ROS levels by redox modulation consti-
tutes a way to selectively induce cancer cell death without causing
significant toxicity to normal cells (261).
HORMONAL LINKS IN OBESITY-ASSOCIATED CANCERS
A substantial number of cancers are linked to a hormonal etiology
such as tumors of the breast, endometrium, ovary, prostate, testis,
and thyroid. Adipose tissue excess is thought to be related with
these types of tumors due to the abnormal levels of several hor-
mones encountered in obesity, most notably increased estrogen
levels (262, 263). Estrogen is a known growth factor with differ-
ent biosynthesis between pre- and post-menopausal women (264).
Pre-menopausal women mainly synthesize estrogens in the ovary,
however, after the menopause peripheral sites including adipose
tissue, are the primary source of estrogens. In this regard, for post-
menopausal women, significant increases in estrone, estradiol, and
free estradiol are associated with increasing BMI (262). Estro-
gen binds to at least three major classes of receptors, ER-α, ER-β,
and GPR30 (265) activating numerous growth-promoting genes,
including growth factors and growth-enhancing protooncogenes
such as c-fos and c-myc (266–268). The primary mediator of post-
menopausal estrogen biosynthesis is aromatase, which is found in
adipose tissue as well as tumor tissue itself (269). In the expand-
ing adipose tissue, this mechanism of production leads to a local
increase in estrogen levels favoring tumor development (15). Dif-
ferent meta-analysis indicated a higher risk of breast cancer in
post-menopausal women with high serum estrogen levels (270,
271). However, the role of blood levels of estrogen in obesity-
associated colon cancer is controversial. Evidence showed a worse
marked effect of obesity in men than women in the carcinogenesis
of colon cancer, pointing to a protective effect of estrogens, which
are increased in obesity (56).
In addition to excess estrogen, hyperplasia and carcinogenesis
may also stem from a decrease in circulating progesterone levels. In
obese women, lack of progesterone due to anovulation, similar to
that observed in the polycystic ovarian syndrome, may contribute
to endometrial cancer risk (272).
OBESITY-ASSOCIATED INSULIN RESISTANCE
Insulin is a key hormone involved in the control of glucose and
lipid homeostasis with insulin actions being mediated by a trans-
membrane insulin receptor, a heterotetrameric glycoprotein con-
sisting of two α-subunits and two β-subunits linked by disulfide
bonds (273). Insulin promotes cellular response through many
pathways, including PI3K/Akt signaling leading to AMPK activa-
tion. AMPK has been implicated in regulating cellular functions
including energy state, fuel metabolism, mitochondrial biogen-
esis, protein and ceramide synthesis, as well as cell growth and
proliferation (274). In addition, its activation was initially shown
to inhibit TNF-α-induced inflammation, insulin resistance, apop-
tosis, and oxidative stress. AMPK activity is diminished in adipose
tissue from severely obese subjects who are insulin resistant com-
pared to equally obese individuals who are insulin sensitive (275).
Studies evaluating insulin secretion, as reflected by C-peptide lev-
els, have pointed out a correlation between hyperinsulinemia and
poor clinical outcome and death in prostate cancer (276). A recent
study has shown that aldo–keto reductase 1B10, which plays a
critical role in tumor development and progression through pro-
moting lipogenesis and eliminating cytotoxic carbonyls, is induced
by insulin through the activator protein-1 (AP-1) signaling path-
way in human hepatocellular carcinoma cells (277). Most recent
reports have also suggested that insulin has mitogenic and anti-
apoptotic effects in endometrial cancer and that the activation
of insulin receptors and Akt is associated with more aggressive
features (278, 279).
Since insulin also acts as a growth factor, there are some mol-
ecules, called insulin-like peptides (ILPs), which can bind to the
insulin receptor and trigger intracellular responses similar to those
triggered by insulin. In humans, the most important ILPs are IGF-1
and IGF-2. The mitogenic and anti-apoptotic environment caused
by elevated levels of insulin and IGF-1 in obesity accelerates the
stepwise accumulation of mutations and, hence, favor carcino-
genesis (280). Studies evaluating IGF-1 circulating concentrations
and cancer risk show important effects on cancer development
and progression. Circulating IGF-1 binds mainly to the major
IGF-binding protein, IGFBP-3 (281). Results of early studies eval-
uating the risk of prostate (282), breast (283), colorectal (284),
and lung cancer (285) suggest that high circulating IGF-1 con-
centrations are associated with an increased risk, whereas high
IGFBP-3 concentrations are associated with a lower risk (286,
287). Associations between IGF-1, IGFBP-3, and cancer risk vary
by cancer site. Circulating concentrations of IGF-1 increase the
risk of non-smoking-related malignant diseases (288). Other ILPs,
like IGF-2, have also been proposed to have a relationship with
carcinogenesis (279).
HYPOXIA, ANGIOGENESIS, AND CANCER DEVELOPMENT
Adipose tissue presents an adequate exposure to nutrients and
oxygen due to the extensive capillary network surrounding each
adipocyte. However, there is substantial evidence that hypoxia
develops in adipose tissue as the tissue mass expands, and the
reduction in O2 concentrations is considered to underlie the
obesity-associated inflammatory response (289). Cancer may
be promoted by the hypoxic and angiogenic environment of
obese adipose tissue, in conjunction with the described elevated
circulating levels of cytokines existing in obese subjects (290).
Studies in hepatocellular carcinoma have shown a higher accu-
mulation of ATM in tumor regions poorly vascularized (291, 292).
Under low oxygen conditions, both tumor cells and macrophages
establish a proangiogenic program mediated by HIF-1, which is
a transcriptional activator complex constituted with two types of
subunits, an inducibleα subunit (HIF-1α, HIF-2α, or HIF-3α), and
the constitutively expressed HIF-1β subunit. Hypoxia stabilizes
HIF-1α, preventing its post-translational hydroxylation and con-
sequently proteasome-mediated degradation. In addition, hypoxia
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promotes HIF-1α association with HIF-1β, as well as cofactor
recruitment (293). HIF-1α is also transcriptionally regulated by
NF-κB (294). ATM adaptation to hypoxia is mediated by the
induction of HIF-1 and HIF-2-regulated genes, including VEGF,
fibroblast growth factor (FGF)-β, and IL-8, as well as glycolytic
enzymes (295). Furthermore, the HIF-1 pathway has been demon-
strated to play a role in macrophage recruitment and activation.
As suggested for NF-κB and STAT-3, HIF-1 might be a potential
target in hepatocellular carcinoma therapy (296). HIF-1 has been
also proposed as a key molecule implicated in tumor metastasis
(297, 298) and a possible metabolic target in cancer therapy (299–
301). Inflammatory molecules like TNF-α are also secreted by
adipose tissue in response to hypoxia and macrophage–monocyte
infiltration (280).
THERAPEUTIC STRATEGIES
Since obesity is a result of a prolonged positive energy balance,
caloric restriction and PA are key strategies to reduce BMI, fat
mass, and improve metabolic abnormalities. Although pharma-
ceutical approaches for obesity and T2D are used, the main pil-
lar of treatment is lifestyle changes. In this regard, it has been
recently reported that behaviors concordant with the Nutrition
and Physical Activity Cancer Prevention Guidelines are associated
with lower risk of total, breast, and colorectal cancers and lower
cancer-specific mortality in post-menopausal women (302).
PHYSICAL ACTIVITY
Sedentary behavior and insufficient PA are strongly related with
obesity and metabolic syndrome development. Animal studies
have shown metabolic beneficial effects of aerobic exercise train-
ing independent of dietary changes (303). However, it has been
demonstrated that the combination of PA and dietary interven-
tion is more effective than only an increase in PA (304). There are
evidences of benefits of physical exercise to normalize obesity-
altered lipid patterns (305, 306), improve glucose metabolism
(307), change the growth hormone/IGF-1 axis (308), and con-
sequently reduce the risk of obesity-associated comorbidities.
Studies in humans have also shown a direct relationship between
BMI, PA, and mortality with cancer (309). In a large cohort study
of middle-age women, both the excess of weight (considered as a
BMI≥ 25 kg/m2) and sedentary habits were significantly associ-
ated with an increased mortality. It has been estimated that excess
weight and physical inactivity could account for 31% of all prema-
ture deaths and 21% of deaths from cancer among non-smoking
women (310). A great variety of studies has reported the advan-
tages of PA in several types of cancer, such as breast (311, 312),
colon (313, 314), or prostate cancer (315).
DIET
Both epidemiological studies and experiments in animals suggest
that alterations in caloric intake or in the quality of the diet may
significantly influence the risk of cancer development and progres-
sion. A higher risk of cancer development related to diets rich in
calories, overabundant in alcohol and animal fats, and/or deficient
in vegetal products has been reported. By contrast, cancer risk was
lower in diets with a higher intake of fruit and vegetables. High-
fiber cereal consumption has also been linked to a reduced risk
of colorectal cancer (16, 316). Recently, the role of ω-3 polyun-
saturated fatty acids in cancer prevention has been highlighted
(317, 318). These fatty acids exert their effects by targeting differ-
ent stages of cancer development, including cell proliferation and
survival, inflammation, or angiogenesis (319, 320).
A cell-cycle regulation by nutrients has been shown in studies
on Saccharomyces cerevisiae. Growth experiments under glucose-
limited conditions suggested that coupling of circadian, metabolic,
and cell division cycles is essential for genome integrity (321).
However, the coupling of these cycles is highly dependent on
the experimental conditions and can be uncoupled under other
nutrient-limiting conditions (322). The relationship between
nutrient availability and genome alterations could play a role in
obesity-related cancer due to an abnormal energy state in obese
subjects. Therefore, aerobic glycolysis or the Warburg effect links
the high rate of glucose fermentation to cancer (323). Moreover,
sugar intake and consumption of sweet cakes and cookies have
been associated with increased risk of endometrial cancer (324).
Biological mechanisms whereby high-sugar foods consumption
might increase risk of cancer development are related to the devel-
opment of hyperglycemia, stimulation of insulin production, and
insulin resistance (325, 326).
Caloric restriction could be a strategy to prevent cancer by
reducing changes induced by obesity and general inflammatory
profile (327). In this regard, studies in prostate cancer and murine
prostate cancer models suggest that caloric restriction and weight
loss may reduce the risk of prostate cancer-specific mortality (71).
Positive effects of weight loss and PA have also been demonstrated
in colorectal cancer (55).
BARIATRIC SURGERY
When PA and dietary changes are not enough to reduce BMI,
bariatric surgery is a useful strategy to reduce excess of fat mass
and prevent weight gain in morbid obesity. There are different sur-
gical techniques that combine variable degrees of restriction and
malabsorption. Beneficial effects of bariatric surgery in reduc-
ing obesity-associated alterations have been largely described. A
clinical improvement in patients with T2D after bariatric surgery
procedures has been shown (328, 329). Noteworthy, there are
studies that suggest a preventive effect of bariatric surgery on
diabetes development (330). Positive effects over other comorbidi-
ties include OSA (331), dyslipidemia (332), hepatic fibrosis (333),
and cardiovascular risk (334, 335). Furthermore, there is evidence
showing that bariatric surgery-induced weight loss reduces cancer
risk in some retrospective cohort studies (336, 337). The mecha-
nisms that may lead to a reduced cancer incidence in subjects under
bariatric surgery include reduction in sex steroid plasma levels;
decreased circulating fatty acid,adipokines, and pro-inflammatory
cytokines levels; improvement in insulin sensitivity and reduction
of fat mass leading to a lower ectopic fat accumulation (338). The
Swedish Obese Subjects (SOS) study, a prospective and controlled
intervention trial involving 2,010 obese patients who underwent
bariatric surgery and 1,037 contemporaneously matched obese
subjects, found a significantly lower number of first-time can-
cers after inclusion in the surgery group (gastric banding, vertical
banded gastroplasty, and gastric bypass) than in the control group,
but only in women. It has been postulated that since gastric
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FIGURE 2 | Proposed mechanisms linking obesity and cancer. The excess
of adipose tissue, especially abdominal obesity, is related to changes in
circulating lipid concentrations, reactive oxygen species levels as well as
adipokine and hormone secretion profile. Obesity is also linked to adipocyte
hypertrophy and hypoxia, aggravating the inflammatory state. Therefore, the
adipose tissue-derived inflammatory cytokines, the production of angiogenic
factors by adipocytes, or infiltrating M1 macrophages that take place in
obesity together with the obesity-associated insulin resistance may promote
the stimulation of a microenvironment favorable for tumorigenesis. CRP,
C-reactive protein; HIF-1α, hypoxia-inducible factor-1α; IGF, insulin growth
factor; IGFBP, insulin-like growth factor-binding protein; IL, interleukin; MCP-1,
monocyte chemoattractant protein 1; MMP, matrix metalloproteinase; OPN,
osteopontin; PAI-1, plasminogen activator inhibitor-1; TGF-β, transforming
growth factor β; TNF-α, tumor necrosis factor α;YKL-40, chitinase-3-like protein.
bypass reduces hyperinsulinemia, this could also be a biological
mechanism by which bariatric surgery exerts protective effects on
cancer incidence (339). Future studies with larger patient num-
bers and longer follow-up periods are required to firmly establish
whether this might also have beneficial effects for men in the long
term (340).
CONCLUSION
Obesity is a potentially avoidable high prevalent risk factor for
developing different health problems including tumor develop-
ment. There are increasing evidences relating obesity and cancer,
with a well-established relationship between obesity and breast,
colorectal, prostate, or lung cancer among others. It has been
proposed that an important percentage of all cancer deaths may
be attributable to obesity. Due to the high prevalence and reper-
cussion of these conditions, the understanding of mechanisms of
obesity-associated tumorigenesis is an important objective in the
prevention and treatment of these pathologies. Future interven-
tions to reduce the prevalence of obesity are needed to prevent
cancer development in these patients. In this regard, it has been
shown that increased PA, healthy dietary habits, and bariatric
surgery may be appropriate to reduce cancer risk in obese patients.
In addition, a comprehensive approximation to the underlying
molecular mechanisms involved in obesity-related carcinogene-
sis may provide specific targets implicated in pathways by which
obesity leads to tumor progression. Reduction of inflammatory
signaling, improvement of insulin sensitivity, or counteracting
the hypoxia-inducible factors appears to be relevant pathways in
prevention of cancer development and reducing its progression
(Figure 2).
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